by Madaline Spencer | Feb 9, 2026
Andrew T. Kuykendall, MD, VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses 52-week results from the VERIFY clinical trial testing rusfertide in patients with polycythemia vera (PV). PV is a...
by Madaline Spencer | Feb 6, 2026
Marius Hoeper, MD, Respiratory Physician at Hannover Medical School, Germany, discusses a recent regulatory update by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in the treatment of pulmonary arterial hypertension...
by Madaline Spencer | Feb 5, 2026
Leonard L. Dragone, MD, PhD, Disease Area Leader in Autoantibody and Rheumatology, Johnson & Johnson Innovative Medicine, discusses positive topline results from a study of nipocalimab in patients with systemic lupus erythematosus (SLE). SLE is an...
by Madaline Spencer | Feb 4, 2026
Shervin Assassi, MD, Director, Division of Rheumatology at McGovern Medical School, discusses the approval of Jascayd (nerandomilast) tablets for treatment of patients with progressive pulmonary fibrosis (PPF). PPF is a subcategory of interstitial lung...
by Madaline Spencer | Feb 3, 2026
Lynn Malec, MD, Versiti Blood Research Institute and Medical College of Wisconsin, discusses results from the XTEND-ed clinical trial evaluating efanesoctocog alfa for the treatment of patients with hemophilia A. Hemophilia A is an inherited bleeding...
